Positron emission tomography and computed tomography with [
PET/CT
Pancreatic cancer
[18F]FDG
[68Ga]Ga-FAPI
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
01
08
2021
accepted:
24
09
2021
pubmed:
16
10
2021
medline:
27
4
2022
entrez:
15
10
2021
Statut:
ppublish
Résumé
This study aimed to investigate the diagnostic performance of [ Patients with suspected or diagnosed pancreatic malignancy, who underwent contemporaneous [ We evaluated 36 participants (25/36 men; median age, 60 years), including 26 patients with pancreatic malignancies and ten patients with pancreatic benign lesions. [ Compared with [
Identifiants
pubmed: 34651226
doi: 10.1007/s00259-021-05576-w
pii: 10.1007/s00259-021-05576-w
doi:
Substances chimiques
Gallium Radioisotopes
0
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1322-1337Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551 .
doi: 10.3322/caac.21551
pubmed: 30620402
pmcid: 30620402
Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57. https://doi.org/10.1016/S0140-6736(04)15841-8 .
doi: 10.1016/S0140-6736(04)15841-8
pubmed: 15051286
NCCN Guidelines for Pancreatic Adenocarcinoma. Version 2.2021. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf . Accessed 25 Feb 2021.
Strobel O, Buchler MW. Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis. Nat Rev Gastroenterol Hepatol. 2013;10(4):203–5. https://doi.org/10.1038/nrgastro.2013.42 .
doi: 10.1038/nrgastro.2013.42
pubmed: 23478386
Heinrich S, Goerres GW, Schafer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242(2):235–43. https://doi.org/10.1097/01.sla.0000172095.97787.84 .
doi: 10.1097/01.sla.0000172095.97787.84
pubmed: 16041214
pmcid: 1357729
Jha P, Bijan B. PET/CT for pancreatic malignancy: potential and pitfalls. J Nucl Med Technol. 2015;43(2):92–7. https://doi.org/10.2967/jnmt.114.145458 .
doi: 10.2967/jnmt.114.145458
pubmed: 25857417
Wakabayashi H, Nishiyama Y, Otani T, Sano T, Yachida S, Okano K, et al. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol. 2008;14(1):64–9. https://doi.org/10.3748/wjg.14.64 .
doi: 10.3748/wjg.14.64
pubmed: 18176963
pmcid: 2673393
Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018;24(19):2047–60. https://doi.org/10.3748/wjg.v24.i19.2047 .
doi: 10.3748/wjg.v24.i19.2047
pubmed: 29785074
pmcid: 5960811
Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH. The role of 18F-FDG PET/CT and PET/MRI in pancreatic ductal adenocarcinoma. Abdom Radiol (NY). 2018;43(2):415–34. https://doi.org/10.1007/s00261-017-1374-2 .
doi: 10.1007/s00261-017-1374-2
Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5–6):454–63. https://doi.org/10.1002/prca.201300095 .
doi: 10.1002/prca.201300095
pubmed: 24470260
Siveke JT. Fibroblast-activating protein: targeting the roots of the tumor microenvironment. J Nucl Med. 2018;59(9):1412–4. https://doi.org/10.2967/jnumed.118.214361 .
doi: 10.2967/jnumed.118.214361
pubmed: 30097504
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801–5. https://doi.org/10.2967/jnumed.119.227967 .
doi: 10.2967/jnumed.119.227967
pubmed: 30954939
pmcid: 6581228
Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47(8):1820–32. https://doi.org/10.1007/s00259-020-04769-z .
doi: 10.1007/s00259-020-04769-z
pubmed: 32222810
Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [(18)F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48(1):73–86. https://doi.org/10.1007/s00259-020-04940-6 .
doi: 10.1007/s00259-020-04940-6
pubmed: 32588089
Nielsen MF, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol. 2016;22(9):2678–700. https://doi.org/10.3748/wjg.v22.i9.2678 .
doi: 10.3748/wjg.v22.i9.2678
pubmed: 26973408
pmcid: 4777992
Rohrich M, Naumann P, Giesel FL, Choyke PL, Staudinger F, Wefers A, et al. Impact of (68)Ga-FAPI PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62(6):779–86. https://doi.org/10.2967/jnumed.120.253062 .
doi: 10.2967/jnumed.120.253062
pubmed: 33097632
pmcid: 8729866
Zhao L, Zhuang Y, Fu K, Chen P, Wang Y, Zhuo J, et al. Usefulness of [(18)F]fluorodeoxyglucose PET/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2020;47(5):1065–74. https://doi.org/10.1007/s00259-019-04654-4 .
doi: 10.1007/s00259-019-04654-4
pubmed: 31897588
Amin MBES, Greene FL, et al. AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.
doi: 10.1007/978-3-319-40618-3
Liermann J, Syed M, Ben-Josef E, Schubert K, Schlampp I, Sprengel SD et al. Impact of FAPI-PET/CT on target volume definition in radiation therapy of locally recurrent pancreatic cancer. Cancers (Basel). 2021;13(4). https://doi.org/10.3390/cancers13040796 .
Wu S, Pang Y, Chen Y, Sun H, Chen H. 68Ga-DOTA-FAPI-04 PET/CT in Erdheim-Chester disease. Clin Nucl Med. 2021;46(3):258–60. https://doi.org/10.1097/RLU.0000000000003491 .
doi: 10.1097/RLU.0000000000003491
pubmed: 33417343
Wu S, Pang Y, Zhao L, Zhao L, Chen H. 68Ga-FAPI PET/CT versus 18F-FDG PET/CT for the evaluation of disease activity in Takayasu arteritis. Clin Nucl Med. 2021. https://doi.org/10.1097/RLU.0000000000003692
Yao L, Zhao L, Pang Y, Shang Q, Chen H. Increased 68Ga-FAPI uptake in ankylosing spondylitis in a patient with rectal cancer. Clin Nucl Med. 2021. https://doi.org/10.1097/RLU.0000000000003798 .
Zhao L, Pang Y, Sun L, Lin Q, Chen H. Increased 68Ga-FAPI uptake in the pulmonary Cryptococcus and the postradiotherapy inflammation. Clin Nucl Med. 2021. https://doi.org/10.1097/RLU.0000000000003873 .
Luo Y, Pan Q, Zhang W, Li F. Intense FAPI uptake in inflammation may mask the tumor activity of pancreatic cancer in 68Ga-FAPI PET/CT. Clin Nucl Med. 2020;45(4):310–1. https://doi.org/10.1097/RLU.0000000000002914 .
doi: 10.1097/RLU.0000000000002914
pubmed: 31977474
Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Gotz TI, Soare A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020;79(11):1485–91. https://doi.org/10.1136/annrheumdis-2020-217408 .
doi: 10.1136/annrheumdis-2020-217408
pubmed: 32719042
Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460–71. https://doi.org/10.1016/S0140-6736(14)60720-0 .
doi: 10.1016/S0140-6736(14)60720-0
pubmed: 25481618
Yu X, Zhu W, Di Y, Gu J, Guo Z, Li H, et al. Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases. Int J Nanomedicine. 2017;12:6771–85. https://doi.org/10.2147/IJN.S131295 .
doi: 10.2147/IJN.S131295
pubmed: 28979117
pmcid: 5602453
Kang MJ, Jang JY, Chang YR, Kwon W, Jung W, Kim SW. Revisiting the concept of lymph node metastases of pancreatic head cancer: number of metastatic lymph nodes and lymph node ratio according to N stage. Ann Surg Oncol. 2014;21(5):1545–51. https://doi.org/10.1245/s10434-013-3473-9 .
doi: 10.1245/s10434-013-3473-9
pubmed: 24419758
Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA. State-of-the-art PET/CT of the pancreas: current role and emerging indications. Radiographics. 2012;32(4):1133–58; discussion 58–60. https://doi.org/10.1148/rg.324115143 .
Yang J, Zhang J, Lui W, Huo Y, Fu X, Yang M, et al. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection. HPB (Oxford). 2020;22(1):91–101. https://doi.org/10.1016/j.hpb.2019.05.015 .
doi: 10.1016/j.hpb.2019.05.015
Pery C, Meurette G, Ansquer C, Frampas E, Regenet N. Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions. Gastroenterol Clin Biol. 2010;34(8–9):465–74. https://doi.org/10.1016/j.gcb.2009.04.014 .
doi: 10.1016/j.gcb.2009.04.014
pubmed: 20688444
Low G, Panu A, Millo N, Leen E. Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. Radiographics. 2011;31(4):993–1015. https://doi.org/10.1148/rg.314105731 .
doi: 10.1148/rg.314105731
pubmed: 21768235
Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1736–44. https://doi.org/10.1245/s10434-009-0416-6 .
doi: 10.1245/s10434-009-0416-6
pubmed: 19387741
Zhao L, Pang Y, Luo Z, Fu K, Yang T, Zhao L, et al. Role of [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [(18)F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(6):1944–55. https://doi.org/10.1007/s00259-020-05146-6 .
doi: 10.1007/s00259-020-05146-6
pubmed: 33415432
Alberts I, Sachpekidis C, Dijkstra L, Prenosil G, Gourni E, Boxler S, et al. The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia. Eur J Nucl Med Mol Imaging. 2020;47(3):642–51. https://doi.org/10.1007/s00259-019-04552-9 .
doi: 10.1007/s00259-019-04552-9
pubmed: 31865408
Mei R, Allegri V, Calabro D, Fanti S, Ambrosini V. Delayed imaging with oral contrast improves [68Ga]Ga-DOTANOC PET/CT detection of primary duodenal neuroendocrine tumor (NET). Eur J Nucl Med Mol Imaging. 2021;48(5):1684–5. https://doi.org/10.1007/s00259-020-05138-6 .
doi: 10.1007/s00259-020-05138-6
pubmed: 33423095
Hoffmann MA, Buchholz HG, Wieler HJ, Rosar F, Miederer M, Fischer N et al. Dual-time point [(68)Ga]Ga-PSMA-11 PET/CT hybrid imaging for staging and restaging of prostate cancer. Cancers (Basel). 2020;12(10). https://doi.org/10.3390/cancers12102788 .